Randomized Trial of Cisplatin versus Firocoxib versus Cisplatin/Firocoxib in Dogs with Transitional Cell Carcinoma of the Urinary Bladder

Journal of Veterinary Internal Medicine

Volumn 27, Issue 1, 2013, Pages 126-133

  Knapp, D W ^a,b   Henry, C J ^c,d   Widmer, W R ^a   Tan, K M ^e,g   Moore, G E ^a   Ramos Vara, J A ^a   Lucroy, M D ⁱ   Greenberg, C B ^a,h   Greene, S N ^j   Abbo, A H ^a,k   Hanson, P D ^f   Alva, R ^f   Bonney, P L ^a  

^a PURDUE UNIVERSITY   (United States)

^b Purdue University   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e PURDUE UNIVERSITY   (United States)

^f BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^g UNIVERSITY OF WASHINGTON   (United States)

^h Veterinary Specialty Center of Utah   (United States)

ⁱ ELANCO ANIMAL HEALTH   (United States)

^j NONE   (United States)

^k New England Veterinary Oncology Group   (United States)

more..

Author keywords

Bladder cancer; Canine; Chemotherapy; Cox inhibitor; Oncology

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DRUG DERIVATIVE; FIROCOXIB; GAMMA BUTYROLACTONE; SULFONE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLADDER TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOG DISEASE; DRUG COMBINATION; FEMALE; GASTROINTESTINAL DISEASE; MALE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TRANSITIONAL CELL CARCINOMA;

4-BUTYROLACTONE; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; MALE; QUALITY OF LIFE; SULFONES; URINARY BLADDER NEOPLASMS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84872418246     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/jvim.12013     Document Type: Article

References (23)

1. Knapp DW. Tumors of the urinary system. In: Withrow SJ, Vail DM, eds. Withrow and MacEwen's Small Animal Clinical Oncology, 4th ed. Philadelphia, PA: WB Saunders; 2007:649-659.
2. Henry CJ, McCaw DL, Turnquist SE, et al. Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. Clin Cancer Res 2003;9:906-911.
3. Knapp DW, Glickman NW, Widmer WR, et al. Cisplatin versus cisplatin combined with piroxicam in a canine model of human invasive urinary bladder cancer. Cancer Chemother Pharmacol 2000;46:221-226.
4. Perazella MA, Moeckel GW. Nephrotoxicity from chemotherapeutic agents: Clinical manifestations, pathobiology, and prevention/therapy. Semin Nephrol 2010;30:570-581.
5. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 2008;11:81s-110s.
6. Dhawan D, Jeffreys AB, Zheng R, et al. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Mol Cancer Ther 2008;7:897-904.
7. Khan KN, Knapp DW, Denicola DB, et al. Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs. Am J Vet Res 2000;61:478-481.
8. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf 2009;8:669-681.
9. Greene SN, Ramos-Vara JA, Craig BA, et al. Effects of cyclooxygenase inhibitor treatment on the renal toxicity of cisplatin in rats. Cancer Chemother Pharmacol 2010;65:549-556.
10. Suddek GM, El-Kenawi AE, Abdel-Aziz A, et al. Celecoxib, a selective cyclooxygenase-2 inhibitor, attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity. Chemotherapy 2011;57:321-326.
11. Yamamato E, Izawa T, Sawamoto O, et al. Amelioration of cisplatin-induced rat renal lesions by a cyclooxygenase (COX)-2 selective inhibitor. Exp Toxicol Pathol 2012;64:625-631.
12. Arúajo AM, Mendez JC, Coelho AL, et al. Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer. Cancer Invest 2009;27:391-396.
13. Autefage A, Palissier FM, Asimus E, et al. Long-term efficacy and safety of firocoxib in the treatment of dogs with osteoarthritis. Vet Rec 2011;168:617.
14. Joubert KE. The effects of firocoxib (Previcox) in geriatric dogs over a period of 90 days. J S Afr Vet Assoc 2009;80:179-184.
15. Owen LN. TNM Classification of Tumors in Domestic Animals, 1st ed. Geneva: World Health Organization; 1980:34.
16. Chun R, Knapp DW, Widmer WR, et al. Phase II clinical trial of carboplatin in canine transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1997;11:279-283.
17. Veterinary C-OOG. Veterinary co-operative oncology group- Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
18. Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-358.
19. D D, Craig BA, Cheng L, et al. Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther 2010;9:1371-1377.
20. Khan Z, Khan N, Tiwari RP, et al. Biology of cox-2: An application in cancer therapeutics. Curr Drug Targets 2011;12:1082-1093.
21. Köberle B, Tomicic MT, Usanova S, et al. Cisplatin resistance: Preclinical findings and clinical implications. Biochim Biophys Acta 2010;1806:172-182.
22. McMillan SK, Boria P, Moore GE, et al. Antitumor effects of deracoxib treatment in 26 dogs with transitional cell carcinoma of the urinary bladder. J Amer Vet Med Assoc 2011;239:1084-1089.
23. Knapp DW, Glickman NW, DeNicola DB, et al. Naturally-occurring canine transitional cell carcinoma of the urinary bladder: A relevant model of human invasive bladder cancer. Urol Oncol 2000;5:47-59.